A fluorescent prodrug to fight drug-resistant lung cancer cells via autophagy-driven ferroptosis.

Lung cancer is the second most common malignant tumor worldwide. The problem of drug resistance in lung cancer leads to treatment failure and recurrence in more than 90% of cancer patients. Thus, developing chemical probes that can observe drug-resistant lung cancer cells in real-time and eliminate them is of great interest. However, such tools that can simultaneously probe drug-resistant lung cancer cells and therapeutic modes of action have not yet been developed. In this work, we reported a fluorescent prodrug that can be activated in cancer cell lysosomes to release amonafide (ANF) and aniline mustard, where the fluorescent signal of ANF (λ ex /λ em = 405/570 −620 nm) can be tracked by super-resolution imaging in live cancer cells. With imaging studies, we found that this new fluorescent prodrug uniquely displays an autophagy-driven ferroptosis-inducing effect, accompanied by the accumulation of intracellular ferrous ions and lipid peroxidation. More importantly, the fluorescent prodrug exhibits potential anti-proliferative activity, especially against drug-resistant A549R lung cancer cells (IC 50 , ∼ 3 μM), better than the positive control drug cisplatin (IC 50 , ∼ 27 μM). This work indicates that the development of fluorescent prodrugs as autophagy-driven ferroptosis inducers may represent a viable approach for targeting drug-resistant cancer cells. [Display omitted] • A new fluorescent prodrug for fighting drug-resistant lung cancer cells was developed. • This fluorescent prodrug can be activated in cancer cell lysosomes to release ANF. • The fluorescent signal of ANF can be tracked by super-resolution imaging in live cells. • This new fluorescent prodrug displays an autophagy-driven ferroptosis-inducing effect. [ABSTRACT FROM AUTHOR]